A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma by John E. Janik, Langdon L. Miller, Edward L. Korn, Diane Stevens, Brendan D. Curti, John W. Smith, Mario Sznol, Kevin C. Conlon, William Sharfman, Walter J. Urba, Barry L. Gause, and Dan L. Longo Blood Volume 97(7):1942-1946 April 1, 2001 ©2001 by American Society of Hematology

Schema for treatment with GM-CSF priming, topotecan, and postchemotherapy GM-CSF. John E. Janik et al. Blood 2001;97:1942-1946 ©2001 by American Society of Hematology

Granulocyte counts in randomized patients treated with and without GM-CSF priming.Geometric mean curves (with approximate 66% confidence limits) of individual patient granulocyte counts for patients treated with topotecan with (n = 23) and without (n = 26) ... Granulocyte counts in randomized patients treated with and without GM-CSF priming.Geometric mean curves (with approximate 66% confidence limits) of individual patient granulocyte counts for patients treated with topotecan with (n = 23) and without (n = 26) GM-CSF priming. Individual patient curves were linearly interpolated on a log scale for days with missing values. John E. Janik et al. Blood 2001;97:1942-1946 ©2001 by American Society of Hematology